By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cellular Dynamics International said today it has closed on a Series B Preferred Stock financing round, raising $30 million.

The financing will be used by the Madison, Wis.-based pluripotent stem cell development firm to launch new iCell induced pluripotent stem cell lines, as well as iCell Endothelial Cells, iCell Neurons, and iCell Hepatocytes for biomedical and pharmaceutical drug development and safety research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.